A BC 3 Bridging the Gap
partner journal
Advanced Breast Cancer
THE
BREAST An Associate Journal of the Australasian Society for Breast Disease Affiliated with the European Society of Breast Cancer Specialists Official Journal of the Breast Centres Network
5-7 November 2015 • Lisbon, Portugal dedicated media partner
Third International Consensus Conference
September-October 2014
Conference Chairs: F. Cardoso, PT
• L. Norton, US
Number 62
OUTWITTING RESISTANCE
• E. P. Winer, US
A SEAT AT THE TABLE
• A. Costa, IT/CH
STEPPING UP
Shelley Dolan
walking alongside patients
FINAL PROGRAMME The ABC3 guidelines will be developed by ESO and ESMO
The ABC3 conference and guidelines are endorsed by
The ABC3 conference is held with support from
under the auspices of
endorsed by
and with official representatives of
Advanced Breast Cancer Third International Consensus Conference
Team Abstract submission
Dolores Knupfer (2) dknupfer@eso.net
Registration
Register online at www.abc-lisbon.org Luis Carvalho (2) lcarvalho@eso.net Laura Richetti (2) lrichetti@eso.net
Accommodation and Optional tours
Helder Carvalho (3) hcarvalho.lisboa@abreu.pt
Organisation
Chatrina Melcher (2) cmelcher@eso.net
Programme secretariat
Dolores Knupfer (2) abc@eso.net Alexandra Zampetti (2) azampetti@eso.net
2
Exhibition, satellite symposia and sponsorship
Francesca Marangoni (1) fmarangoni@eso.net
Communication
Gabriele Maggini (2) gmaggini@eso.net
Press Officers
International media: Emma Mason +44 7711 296986 and Mary Rice +33 6 6893 0650 info@ricemason.eu National media: Filipa Morals +351 211 546 120
1
European School of Oncology Via Turati, 29 20121 Milano, Italy
ph +39 02 85464 525 fx +39 02 85464 545 www.abc-lisbon.org www.eso.net
2
European School of Oncology Piazza Indipendenza 2 6500 Bellinzona, Switzerland
ph +41 91 820 0950 fx +41 91 820 0953 www.abc-lisbon.org www.eso.net
3
Viagens Abreu SA Av. 25 de Abril, 2 2799-556 Linda-a-Velha, Portugal
ph +351 21 415 6120 fx +351 21 415 6383
ABC3 5-7 NOVEMBER 2015, LISBON, PORTUGAL
A BC 3 #ABClisbon
Dear Colleagues,
T
he International Consensus Conference for Advanced Breast Cancer (ABC) has established itself as a major international breast cancer conference. Its primary aim is the development of international consensus guidelines for the management of ABC patients. These guidelines are based on the most up-to-date evidence and can be used to guide treatment decision making in many different health care settings globally, with the necessary adaptations due to different access to care.
The last meeting, which took place in Lisbon, Portugal in November 2013, brought together over 1000 participants from 71 countries around the world, including health professionals, patient advocates and journalists. ABC Consensus Conferences have the ambitious goal of improving outcomes for all patients with advanced breast cancer. We believe that health professionals working closely together with patient advocates and with the strong support of media can raise awareness about the needs and challenges faced by this traditionally underserved and forgotten group of patients. We aim to identify research priorities based on the most important areas of unmet need, analyse and discuss available data to provide the most accurate management recommendations, but also to influence policy makers and funding bodies and ultimately improve standards of care, survival and quality of life. Research and education, with accurate usage of available knowledge, throughout the world, are key to achieve these goals. ABC guidelines are jointly developed by ESO (European School of Oncology) and ESMO (European Society of Medical Oncology) and guidelines or ABC conferences have been endorsed and supported by several other international oncology organizations such as ESGO (European Society of Gynaecological Oncology), EUSOMA (European Society of Breast Cancer Specialists), ESTRO (European Society for Radiotherapy and Oncology), UICC (Union International Contre le Cancer), SIS (Senologic International Society) / ISS (International School of Senology), FLAM (Federacion Latino-Americana de Mastologia), OECI (Organization of European Cancer Institutes), Susan G. Komen速 and BCRF (Breast Cancer Research Foundation). Furthermore, the ABC3 faculty includes official representatives appointed by ASCO (American Society of Clinical Oncology). We strongly believe that together we will dramatically change the poor outcome of this disease and improve both the quality and length of life of all patients living with ABC worldwide. Through our dedicated efforts over this last decade, we can certainly say to every ABC patient "You are no longer forgotten, but you are still our heroes!"*.
Fatima Cardoso, Eric P. Winer, Larry Norton and Alberto Costa Conference Chairs
* Metastatic breast cancer patients: The forgotten heroes! The Breast 18: 271-272, 2009
5-7 NOVEMBER 2015, LISBON, PORTUGAL ABC3
3
Advanced Breast Cancer Third International Consensus Conference
Acknowledgements ESO wishes to express its appreciation and gratitude to the ABC3 Chairs for their support and vision in organising this conference, all faculty members and panellists, and members of the Patient Advocacy Committee for their commitment and contribution to the programme.
ESO’s gratitude is furthermore extended to The Breast and Cancer World for their cooperation, all organisations and companies for participating and supporting the initiative.
General information
Venue ABC3 will be held at the CCL - Centro de Congressos de Lisboa, Praça das Industrias, Lisbon, Portugal. Insurance The organisers bear no responsibility for untoward events in relation to the participation in the Conference. Participants are advised to take out their own personal and travel insurance coverage.
4
ABC3 5-7 NOVEMBER 2015, LISBON, PORTUGAL
Official language The official language will be English. No translation will be provided. Abstract book The abstract book is published as a supplement of The Breast (Volume 24, Supplement 3, November 2015) and contains abstracts of the invited lecturers and those submitted by the participants that have been accepted for oral or poster presentation or for publication only.
A BC 3 #ABClisbon
CME accreditation and certificates Participants will be entitled to receive a certificate of attendance at the close of the Conference by completing the online evaluation questionnaire. The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value. The event is designated for a maximum of 12 European CME credits (ECMEC). Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Furthermore, the conference has been accredited with 11 ESMO-MORA category 1 points. Filming, recording or photographing Conference sessions Filming, recording or photographing Conference sessions is prohibited, unless prior permission has been sought and agreement obtained from the press officers. Filming, recording or photographing in the general areas of the Conference is permitted if prior permission has been sought and agreement obtained from the press officers. Social media
Tweet, network and follow updates using #ABClisbon on Twitter and Facebook and join in the discussions leading up to ABC3 via our blog http://thecancerblog.net.
Third Party Media Policy The policy applies to all activities related to the news media during or in connection with ABC3 and is posted at www.abclisbon.org/pagine-interne/third-party-mediapolicy.html. The aim is to ensure that information distributed to the journalists is accurate and is issued at the correct times, complying with any embargoes that may be in place. The policy applies to media events that are organised at the ABC3 venue and off-site, and all third parties are requested to adhere. No smoking policy ABC3 is a tobacco-free event. All participants are kindly asked to respect the no-smoking policy. Voices of Strength photography exhibit
The Here & Now campaign, a pan-European ABC disease awareness initiative supported by Novartis Oncology, is delighted to be launching Voices of Strength: an exhibition featuring a unique set of photographs of women living with ABC from across Europe. Nearly two-thirds of women living with ABC feel that no-one understands them and nearly 40% feel isolated from others who do not have ABC. Voices of Strength photographs women with ABC alongside their own words of strength to demonstrate their positivity and wisdom, ultimately highlighting their presence and value within our society. The striking photographs and empowering words of these women also aim to provide inspiration to others on their ABC journeys. Delegates are invited to immerse themselves in the exhibit and be moved and motivated by the women who inspire the collective goal to improve the management and care of ABC. The exhibit is held in Auditorium II on Thursday, 5 November and Friday, 6 November.
5-7 NOVEMBER 2015, LISBON, PORTUGAL ABC3
5
Advanced Breast Cancer Third International Consensus Conference
Conference speakers and panellists Conference speakers and panellists are invited to refer to the speakers room located on Level 1. Presentation files should be delivered to the appointed technician in the speakers room 30 minutes or more before the start of the session. Press office Accredited journalists wearing a “media representative” badge are invited to refer to the press office located on Level 1. Coffee breaks, lunches and welcome cocktail Coffee breaks, lunches and welcome cocktail are available to all participants, media representatives and exhibitors during the published times. Buffets are organised on Level 1 in the poster and in the catering areas. Furthermore, please note that the poster session is scheduled on Friday, 6 November during lunch time. During the poster session, the appointed faculty members will visit and discuss the posters with the presenters and participants. Registration desk, opening hours Wednesday, 4 November 10:00-18:00 Thursday, 5 November 8:00-20:00 Friday, 6 November 8:30-20:00 Saturday, 7 November 8:00-13:30 Exhibition, opening hours Thursday, 5 November Friday, 6 November Saturday, 7 November
9:00-19:30 9:00-19:30 8:30-13:00
Official carrier
ESO is grateful to Star Alliance™ members airlines who supported the Conference as the Official Airline Network for ABC3 and offered discounted fares to the participants.
6
ABC3 5-7 NOVEMBER 2015, LISBON, PORTUGAL
Registration Admission to the sessions is granted to faculty members, panellists, participants and media representatives who hold a full registration. Furthermore, registration grants a copy of the programme and of the abstract book, coffee breaks, lunches, welcome cocktail as indicated in the programme. Representatives of exhibiting companies do not have access to the sessions but to all other services. Badge The badge is the only official evidence of registration and should be worn at all times during the event. Loss of badge causes loss of registration. Regular registration fees
Early
Late
On-site
(by 31 July)
(by 16 October)
(after 16 October)
EUR 530
EUR 680
Registration fee
EUR 430
Club ESO Members
EUR 320
ESMO Members
EUR 320
Cancellation Replacement or refund of registration fees (less handling charges of EUR 100) was possible for notification to ESO by 1 October. Group registration The group registration procedure was available for groups of 5 or more individuals, and foresees that the group leader’s instructions regarding the collection of the on-site materials (badge, delegates bag) are followed. For any query, please refer to the group registration desk on-site. Nurses and Patient Advocates Nurses and representatives of cancer patient advocacy non-profit organisations are eligible for a discounted registration fee by submitting the following documents:
A BC 3 #ABClisbon
• Nurses: curriculum vitae with full contact
details • Patient advocates: curriculum vitae or resume indicating the advocacy experience, role within the organisation and the full contact details of the patient advocate organisation.
Registration fee
Early
Late
On-site
(by 31 July)
(by 16 October)
(after 16 October)
EUR 230
EUR 280
EUR 380
Media Registration The Conference welcomes representatives of print and electronic media. Registration is free of charge to journalists who are in possession of a valid, recognised press card. Freelance journalists must present a commissioning letter on headed paper from a recognised news organisation or publication. Representatives of advertising, marketing and public relations companies are not eligible for free media registration. A copy of the Press Card or of the commissioning letter should be provided together with the media registration form.
Public transportation Public transportation is available from the hotels and the congress centre.
Distance km/time
Public transportation
Pestana Palace
0,8/8’
(walking dist)
Jeronimos 8
2,5/15’
A
Vila Gale Opera
0,3/3’
(walking dist)
Tivoli Lisboa
5/20’
B
Altis Grand
5/20’
B
Tivoli Jardim
5/20’
B
Marques de Pombal
5/20’
B
Fenix Lisboa
5/20’
B
Fenix Garden
5/20’
B
Hotel
A
Tram 15 or Bus 28
B
From hotel to venue: Bus 732 then Tram 15 or Bus 28
Belem Belem
Praça do Comercio (city centre) Praça do Comercio (city centre)
Praça do Comercio (city centre) Avenida da Liberdade Belem Praça do Comercio (city centre) Belem Praça do Comercio (city centre)
The stop at the Congress Centre is called “Rua Junqueira”.
5-7 NOVEMBER 2015, LISBON, PORTUGAL ABC3
7
BOOKING YOUR OWN CONFERENCE TRAVEL IS EASY AS ABC WITH THE GLOBAL ONLINE BOOKING TOOL FROM STAR ALLIANCE CON VENTION S PLUS No matter where you are travelling from, the Star Alliance™ network offers you a wide choice of flights to the ABC3 in Lisbon, Portugal. And with over 18,500 flights a day to 1,316 destinations across 192 countries, our 27 member airlines extend the same choice to any future conferences you are planning to attend. You can also save money when you book your flights. Simply quote the Convention Code TP04S15 and you plus one travelling companion will receive a special discount. Better still, no matter which Star Alliance member airline’s frequent flyer programme you belong to, you can earn and redeem miles across all 27 airlines. For more information, or to join the airline network that offers you more choice wherever your conferences take you, simply go to www.staralliance.com/conventionsplus
www.staralliance.com Information correct as of 07/2014
A BC 3 #ABClisbon
ABC conference and consensus guidelines Advanced Breast Cancer First Consensus Conference 3-5 November 2011 The guidelines are published in The Breast 21 (2012) 242-252.
Advanced Breast Cancer Second International Consensus Conference 7-9 November 2013 The guidelines were jointly developed by ESO and ESMO and are published simultaneously in The Breast and Annals of Oncology journals. The guidelines are available here: http://www.abc-lisbon.org/pagine-interne/downloads.html The ABC2 guidelines are furthermore endorsed by: and the Conference was held under the auspices of:
Advanced Breast Cancer Third International Consensus Conference 5-7 November 2015 ESO is pleased to announce that also the ABC3 guidelines will be developed jointly by ESO and ESMO and published simultaneously in The Breast and Annals of Oncology journals. Furthermore, the ABC3 conference is endorsed by:
under the auspices of
held with support from
is CME accredited by
The ABC3 guidelines are endorsed by
and
labelled
and will be submitted for endorsement to
The ABC3 faculty includes official representatives appointed by
5-7 NOVEMBER 2015, LISBON, PORTUGAL ABC3
9
Bridging the Gap
Advanced Breast Cancer 9-11 November 2017
Lisbon, Portugal
Fourth International Consensus Conference
SAVE THE DATE RECEIVE UPDATES AT: WWW.ABC-LISBON.ORG
#ABClisbon
Chairs: F. Cardoso, PT L. Norton, US E.P. Winer, US A. Costa, IT/CH
A BC 3 #ABClisbon
ABC Award The ABC Award is aimed at recognising a researcher, physician, nurse or patient advocate who has made an outstanding and impacting contribution in the field of advanced breast cancer throughout his/her career. The first ABC Award - in recognition of his work on discovering fundamental, clinically-relevant biological and molecular mechanisms for metastases including site specificity, latency, self-seeding and the role of the microenvironment in colonization and drug resistance - was assigned to Joan MassaguĂŠ.
The Award Ceremony during ABC2 7 November 2013 Prof. Joan MassaguĂŠ (right) receiving the Award from the Conference Chair, Dr. Larry Norton.
The second ABC Award - in recognition for his work on metastatic breast cancer, especially improving the management of metastatic cancer to bone, resulting in preservation and improvement in quality of life of patients worldwide - will be assigned to Robert E. Coleman during the Award Ceremony on 5 November.
ABC3 Award selection committee Monica Castiglione, Department of Medicine, Geneva University, Geneva, CH Gabriel N. Hortobagyi, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, US Musa Mayer, AdvancedBC.org, New York, US
5-7 NOVEMBER 2015, LISBON, PORTUGAL ABC3
11
Advanced Breast Cancer Third International Consensus Conference
High Patronage The European School of Oncology is proud to announce that the Conference is held under the High Patronage of His Excellency the President of the Portuguese Republic and is honoured that Mrs. Maria Cavaco Silva, First Lady of the Portuguese Republic, will welcome ABC3 participants to Lisbon and open the Conference.
ABC3 Chairs Larry Norton
Fatima Cardoso Breast Unit, Champalimaud Cancer Center, Lisbon, PT
Breast Cancer Programs, Memorial Sloan-Kettering Cancer Centre, New York, US
Alberto Costa
Eric P. Winer
Scientific Director, European School of Oncology, Milan, IT and Bellinzona, CH
Breast Oncology Center, Dana-Farber Cancer Institute, Boston, US
Faculty members Matti S. Aapro
Maria João Cardoso
IMO Clinique De Genolier, Institut Multidisciplinaire d'Oncologie, Genolier, CH
Breast Unit, Champalimaud Cancer Center and MamaHelp, Lisbon, PT
Fabrice André
Lisa A. Carey
Department of Medical Oncology, Gustave Roussy Institute, Villejuif, FR
Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, North Carolina, US
Sam Aparicio Department of Breast and Molecular Oncology, University of British Columbia and the BC Cancer Agency, Vancouver, CA
Sarbani Chaudhuri
Carlos H. Barrios
Academic Unit of Clinical Oncology, University of Sheffield & Weston Park Hospital, Sheffield, UK
Department of Medicine, PUCRS School of Medicine, Porto Allegre, BR
Robert E. Coleman Dian “CJ” M. Corneliussen-James
Marc Beishon
METAvivor Research and Support, Annapolis, US
Cancer World, London, UK
Giuseppe Curigliano
Jonas Bergh
Division of Experimental Therapeutics, European Institute of Oncology, Milan, IT
Department of Oncology-Pathology, Karolinska Institute, Stockholm, SE
Gouri S. Bhattacharyya Department of Medical Oncology, Fortis Hospital, Kolkata, IN
Laura Biganzoli Department of Medical Oncology, Sandro Pitigliani Oncology Centre, Prato, IT
12
Pfizer Oncology, New York, US
ABC3 5-7 NOVEMBER 2015, LISBON, PORTUGAL
Véronique Dieras Department of Medical Oncology, Institut Curie, Paris, FR
Nagi S. El Saghir NK Basile Cancer Institute, American University of Beirut Medical Center, Beirut, LB
A BC 3 #ABClisbon
Alexander Eniu
Frédérique Penault-Llorca
Department of Breast Tumors, Cancer Institute "I. Chiricuta", Cluj-Napoca, RO
Department of Pathology, Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, FR
Lesley Fallowfield
Martine J. Piccart
Sussex Health Outcomes Research & Education in Cancer, Brighton & Sussex Medical School, University of Sussex, Brighton, UK
Department of Medicine, Jules Bordet Institute, Brussels, BE
Doris Fenech
Jean-Yves Pierga
Breast Care Support Group, Europa Donna Malta, Mtarfa, MT
Department of Medical Oncology, Institut Curie, Paris Cancer Center, Paris, FR
Patrick Flamen
Fausto Roila
Department of Nuclear Medicine, Jules Bordet Institute, Brussels, BE
Department of Medical Oncology, Monteluce Policlinic, Perugia, IT
Prudence A. Francis
Hope S. Rugo
Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, AU
Breast Oncology and Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
Karen Gelmon Department of Medical Oncology, BC Cancer Agency, Vancouver, CA
Kimberly A. Sabelko
Alessandra Gennari
Elzbieta Senkus-Konefka
Department of Medical Oncology, Galliera Hospital, Genoa, IT
Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, PL
Nadia Harbeck
Lillie D. Shockney
Breast Center, University of Munich, Munich, DE
Department of Surgery and Oncology, Johns Hopkins Breast Center, Baltimore, US
Jens Hoffmann EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH, Berlin, DE
Clifford A. Hudis
Susan G. Komen, Dallas, US
George W. Sledge Division of Oncology, Stanford School of Medicine, Stanford, US
Breast Medicine Service, Memorial SloanKettering Cancer Centre, New York, US
Danielle Spence
Bella Kaufman
Richard Sullivan
Department of Oncology, Sheba Medical Center, Tel Hashomer, IL
Conflict & Health Research Program, Institute of Cancer Policy, London, UK
Ian E. Krop
Sandra M. Swain
Breast Oncology Center, Dana-Farber Cancer Institute, Boston, US
Washington Cancer Institute, MedStar Washington Hospital Center, Washington DC, US
Stella Kyriakides
David G. Taylor
Europa Donna Cyprus, Nicosia, CY
Musa Mayer
School of Pharmacy, University College London, London, UK
AdvancedBC.org, New York, US
Christoph Thomssen
Hanneke Meijer
Clinic for Gynaecology, Martin-Luther-Universität, Klinikum Kröllwitz, Halle (Saale), DE
Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, NL
Shirley A. Mertz Metastatic Breast Cancer Network US, Inverness, US
Shinji Ohno Breast Oncology Centre, Cancer Institute Hospital, Tokyo, JP
Olivia Pagani Breast Unit, Oncology Institute of Southern Switzerland, Bellinzona, CH
Evi Papadopoulos Europa Donna, Nicosia, CY
Fedro A. Peccatori Deputy Scientific Director, European School of Oncology, Milan, IT and Bellinzona, CH
Breast Cancer Network Australia, Camberwell, AU
Luzia Travado Department of Psycho-Oncology, Champalimaud Clinical Centre, Lisbon, PT
Andrew Tutt Breakthrough Breast Cancer Research Unit, King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Daniel A. Vorobiof Sandton Oncology Centre, Johannesburg, ZA
Binghe Xu Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN
5-7 NOVEMBER 2015, LISBON, PORTUGAL ABC3
13
Advanced Breast Cancer Third International Consensus Conference
Breast cancer patient advocacy programme Representatives of breast cancer patient advocacy groups are warmly invited to participate in ABC3 and actively contribute to the scientific programme and consensus session.
Furthermore, in collaboration with several leading breast cancer patient advocacy groups worldwide, specific additional patient advocacy sessions have been scheduled.
Breast Cancer Patient Advocacy Committee Coordinator: Fatima Cardoso Breast Unit, Champalimaud Cancer Center, Lisbon, PT
Marc Beishon
Shirley A. Mertz
Cancer World, London,UK
Metastatic Breast Cancer Network US, Inverness, US
Maria João Cardoso MamaHelp, Lisbon, PT
Dian “CJ” M. Corneliussen-James METAvivor Research and Support, Annapolis, US
Musa Mayer AdvancedBC.org, New York, US
Evi Papadopoulos Europa Donna, Nicosia, CY
Danielle Spence Breast Cancer Network Australia, Camberwell, AU
Kimberly A. Sabelko Susan G. Komen, Dallas, US
14
ABC3 5-7 NOVEMBER 2015, LISBON, PORTUGAL
A BC 3 #ABClisbon
Breast cancer patient advocacy sessions Thursday, 5 November 9:00-10:30
Worldwide survey and call to action (Chairs: F. Cardoso, PT and D. “CJ” M. Corneliussen-James, US)
10:30-11:00
“I am Anna” Video presentation and viewing (S. Ginsberg, CA and A. Craig, CA)
11:00-12:30
Specific issues of young women with advanced breast cancer (Chairs: E. Papadopoulos, CY and D. Spence, AU)
16:15-16:40
“I am Anna” Q+A session based on the video screened in the morning (S. Ginsberg, CA and A. Craig, CA)
18:00-19:30
Advanced breast cancer symptom control (Chairs: M.J. Cardoso, PT and S.A. Mertz, US)
Friday, 6 November 18:00-19:30
ABC Advocacy: wrap-up and call to action (Chairs: M. Beishon, UK and M. Mayer, US)
Saturday, 7 November 11:00-11:15
Report from ABC Patient Advocacy Committee (S.A. Mertz, US)
For the sessions’ details, please refer to the programme.
5-7 NOVEMBER 2015, LISBON, PORTUGAL ABC3
15
Advanced Breast Cancer Third International Consensus Conference
Floor plan
POSTERS
AUDITORIUM III/IV
AUDITORIUM I CATERING AREA
ROOM 1.14
WISEPRESS IGEA
ROOM 1.08
CATERING AREA
ROOM 1.07 ESO NOVARTIS EUROPA DONNA
EISAI
ROOM 1.06 EISAI HOSPITALITY SUITE PFIZER ONCOLOGY MEETING SUITE ROOM 1.05
AUDITORIUM II PFIZER ONCOLOGY
SPEAKERS ROOM
PRESS ROOM
CATERING AREA
16
ABC3 5-7 NOVEMBER 2015, LISBON, PORTUGAL
ROOM 1.02
A BC 3 #ABClisbon
Programme schedule Wednesday 4 November
Thursday, 5 November
Friday, 6 November
Saturday, 7 November
9:00 - 19:30 Exhibition
9:00 - 19:30 Exhibition
8:30 - 13:00 Exhibition
9:00 - 10:30 Breast cancer patient advocacy session
9:00 - 10:00 Revolutionizing ER+ ABC management
8:30 - 10:30 Consensus session (part I)
10:00 - 10:30 Coffee break 10:30 - 11:00 Coffee break 10:30 - 11:00 Breast cancer patient advocacy video presentation
10:30 - 11:35 Triple-negative: Is hope around the corner?
10:00 Registration opens
11:00 - 12:30 Breast cancer patient advocacy session
10:30 - 11:00 Coffee break 11:00 - 11:15 Report from ABC Patient Advocacy Committee 11:15 - 12:45 Consensus session (part II)
11:00 - 12:30 Satellite symposium 2
11:35 - 12:10 New technologies and new techniques
12:30 - 13:30 Lunch
12:10 - 12:45 Supportive and palliative care
13:30 - 14:25 Opening session
12:45 - 13:45 Lunch and Poster session
14:25 - 15:30 Optimal management of HER-2+ ABC
13:45 - 14:40 Biology, biology, biology!
15:30 - 16:15 Best abstract presentations
15:45 - 16:15 Coffee break
16:15 - 16:40 Coffee break
16:15 - 17:00 Survivorship in ABC
12:45 - 13:00 Close
14:40 - 15:45 Clinical dilemmas in ABC
16:15 - 16:40 Breast cancer patient advocacy video Q&A session
16:40 - 17:40 New drugs, new side effects
17:00 - 18:00 Affordability and access to care
17:40 - 18:00 ABC3 Award and Lecture 18:00 - 19:30 Breast cancer patient advocacy session
18:00 - 19:30 Breast cancer patient advocacy session
18:00 - 19:30 Satellite symposium 3
18:00 - 19:30 Satellite symposium 4
Welcome cocktail
A/V Recording during the Conference is prohibited.
5-7 NOVEMBER 2015, LISBON, PORTUGAL ABC3
17
Advanced Breast Cancer Third International Consensus Conference
Programme Thursday, 5 November 9:00-10:30 Audit. III/IV 9:00 9:05 9:20 9:45 10:05 10:30-11:00
Breast cancer patient advocacy session: Worldwide survey and call to action (Chairs: F. Cardoso, PT and D. “CJ” M. Corneliussen-James, US) Welcome and introduction The mBCVision 2025 Project: why, how and what? (S. Chaudhuri, US) Main findings of the mBCVision 2025 Project (F. Cardoso, PT) Main findings of the mBCVision 2025 Project: implications for patients (D. “CJ” M. Corneliussen-James, US) Discussion on call to action points Coffee break
10:30-11:00 Audit. III/IV
Breast cancer patient advocacy session: “I am Anna” (* see next page) Video presentation and viewing (S. Ginsberg, CA and A. Craig, CA)
11:00-12:30 Audit. III/IV
Breast cancer patient advocacy session: Specific issues of young women with advanced breast cancer (Chairs: E. Papadopoulos, CY and D. Spence, AU) Introduction (E. Papadopoulos, CY) Presentation of key issues (L. Travado, PT) • Relationships/sexuality/personality/social image - how women relate to themselves, their partners and their social networks • Practical issues- work, finances, home support, including childcare • Emotional concerns of those close to you, including children, partners, parents What are the requirements to assist women to address these issues? (D. Spence, AU) Empowering women (S. Kyriakides, CY) Q+A session (D. Spence, AU) Closing remarks (D. Spence, AU)
11:00 11:15
11:35 11:55 12:10 12:25 11:00-12:30 Audit. I
Sponsored satellite symposium 2 (details are available on page 32)
12:30-13:30
Lunch
13:30-14:25 Audit. I 13:30 13:40 14:00
Opening session (Chairs: F. Cardoso, PT and L. Norton, US) Welcome to Lisbon (Maria Cavaco Silva, First Lady of the Portuguese Republic) Opening and introduction (F. Cardoso, PT) Keynote lecture: METAvivor: fighting prejudice! [abstract IN02] (D. “CJ” M. Corneliussen-James, US) A/V Recording during the Conference is prohibited.
18
ABC3 5-7 NOVEMBER 2015, LISBON, PORTUGAL
A BC 3 #ABClisbon
14:25-15:30 Audit. I 14:25 14:40 14:55 15:10 15:25
Optimal management of HER-2+ ABC (Chairs: S. Ohno, JP and E.P. Winer, US) Is there an optimal treatment sequence? [abstract IN03] (S.M. Swain, US) Resistance to anti-HER-2 agents: what's new [abstract IN04] (I.E. Krop, US) Long term survivors specific issues [abstract IN05] (K. Gelmon, CA) Long term survivors: living on borrowed time [abstract IN06] (S.A. Mertz, US) Discussion
15:30-16:15 Audit. I 15:30
Best abstract presentations (Chairs: A. Costa, IT/CH and K.A. Sabelko, US) Unmet psychosocial and quality of life needs of patients living with metastatic breast cancer [abstract OR37] (M. Hurlbert, US) No impact of increasing symptoms on quality of life? Longitudinal data from the German MALIFE-Project on patients receiving monochemo- and endocrine treatment for advanced breast cancer - results from the TMK registry group [abstract OR51] (N. Marschner, DE) CTL and IgG response to tumor-associated antigens as predictive factors of therapeutic peptide vaccination for patients with metastatic recurrent breast cancer [abstract OR128] (U. Toh, JP)
15:45
16:00
16:15-16:40 16:15-16:40 Audit. III/IV
Coffee break Breast cancer patient advocacy session: “I am Anna” Q+A session based on the video screened in the morning (*) (S. Ginsberg, CA and A. Craig, CA) * ”I am Anna”: The video tells the insightful story of Anna Craig: a mother, wife, artist, architect and young woman living with metastatic breast cancer. The film follows Anna’s inspiring journey to create her legacy by building an addition to her house that fulfils her artistic dreams and leaves something special for her family. Through this process we also watch her help to build a support network for young metastatic women. I AM ANNA is produced by Rethink Breast Cancer. The video is screened in the morning and, in the afternoon, the presenters will hold a questions and answers session.
16:40-17:40 Audit. I 16:40 16:55 17:10 17:25
New drugs, new side effects (Chairs: E. Papadopoulos, CY and E. Senkus-Konefka, PL) Endocrine [abstract IN07] (A. Eniu, RO) Pulmonary [abstract IN08] (H.S. Rugo, US) Immunologic alterations [abstract IN09] (C.H. Barrios, BR) The role of Patient Reported Outcomes [abstract IN10] (L. Fallowfield, UK)
17:40-18:00 Audit. I
ABC Award and Lecture: Living with metastatic bone disease - the positive impact of bone-targeted treatments [abstract IN01] (Chair: L. Norton, US - Awardee: R.E. Coleman, UK)
A/V Recording during the Conference is prohibited.
5-7 NOVEMBER 2015, LISBON, PORTUGAL ABC3
19
Advanced Breast Cancer Third International Consensus Conference
18:00-19:30 Audit. III/IV 18:00 18:20 18:45 19:05 18:00-19:30 Audit. I 19:30
Breast cancer patient advocacy session: Advanced breast cancer symptom control (Chairs: M.J. Cardoso, PT and S.A. Mertz. US) Pain medication: is it universally available to ABC patients? Is it a patient and/or human right in ABC? (A. Eniu, RO) Discussion (M.J. Cardoso, PT and S.A. Mertz. US) Barriers to active patient reporting of quality of life symptoms/outcomes in the ABC setting (L. Fallowfield, UK) Discussion (M.J. Cardoso, PT and S.A. Mertz. US) Sponsored satellite symposium 3 (details are available on page 32) Welcome cocktail
Friday, 6 November 9:00-10:00 Audit. I 9:00 9:20 9:35 9:50
Revolutionizing ER+ ABC management (Chairs: M.J. Piccart, BE and B. Xu, CN) The role of CDK and PI3K/mTOR inhibitors [abstract IN12] (F. AndrĂŠ, FR) ESR1 and other suspects in resistance [abstract IN13] (V. Dieras, FR) Is ovarian ablation mandatory in pre-menopausal ER+ ABC patients? [abstract IN14] (J. Bergh, SE) Discussion
10:00-10:30
Coffee break
10:30-11:35 Audit. I 10:30 10:45 11:00 11:15 11:30
Triple negative: is hope around the corner? (Chairs: N.S. El Saghir, LB and E.P. Winer, US) Current optimal management [abstract IN15] (L.A. Carey, US) Resurrecting PARP inhibition [abstract IN16] (A. Tutt, UK) Can immune-based therapies be the key? [abstract IN17] (G. Curigliano, IT) The role of androgen receptor and its inhibitors [abstract IN18] (C.A. Hudis, US) Discussion
11:35-12:10 Audit. I 11:35
New technologies and new techniques (Chairs: L.A. Carey, US and F.A. Peccatori, IT/CH) New tools in nuclear medicine: what can they offer for ABC patients [abstract IN19] (P. Flamen, BE) New radiotherapy techniques: application in ABC [abstract IN20] (H. Meijer, NL) Discussion
11:50 12:05 12:10-12:45 Audit. I 12:10 12:25 12:40
Supportive and palliative care (Chairs: L. Biganzoli, IT and D. Spence, AU) Optimal management of fatigue [abstract IN21] (F. Roila, IT) Dyspnea: the hardest symptom to control? [abstract IN22] (M.S. Aapro, CH) Discussion
A/V Recording during the Conference is prohibited.
20
ABC3 5-7 NOVEMBER 2015, LISBON, PORTUGAL
A BC 3 #ABClisbon
12:45-13:45
Lunch and poster session (details are available on page 24-27) The appointed faculty members will visit and discuss the posters with the presenters and participants: • Nursing
(D. Fenech, MT and L.D. Shockney, US) • Patient advocacy
(D. “CJ” Corneliussen-James, US, M. Mayer, US, S.A. Mertz, US and E. Papodopoulos, CY) • Clinical issues: Medical oncology (J. Bergh, SE, P.A. Francis, AU, K. Gelmon, US and O. Pagani, CH) • Clinical issues: Radiation oncology (H. Meijer, NL and E. Senkus-Konefka, PL) • Clinical issues: Surgical oncology (A. Costa, CH/IT and M.J. Cardoso, PT) • Clinical issues: Supportive and palliative care (M.S. Aapro, CH, N.S. El Saghir, LB, A. Gennari, IT and D.A. Vorobiof, ZA) • Clinical issues: Other topics (C.H. Barrios, BR, A. Eniu, RO, H.S. Rugo, US and C. Thomssen, DE) • Basic and translational research (F. André, FR, V. Dieras, FR and N. Harbeck, DE) 13:45-14:40 Audit. I 13:45 14:05 14:25 14:40-15:45 Audit. I 14:40 14:55 15:10 15:25 15:40
Biology, biology, biology! (Chairs: L. Norton, US and F. Penault-Llorca, FR) Circulating tumor cells and tumor DNA: are liquid biopsies a dream? [abstract IN23] (J.Y. Pierga, FR) Intra-tumor heterogeneity: challenges and solutions [abstract IN24] (S. Aparicio, CA) Patient xenograph models: can an "avatar" help? [abstract IN25] (J. Hoffmann, DE) Clinical dilemma’s in ABC (Chairs: B. Kaufman, IL and D.A. Vorobiof, ZA) Biopsy, rebiopsy and dealing with discordant results [abstract IN26] (N. Harbeck, DE) Is there an optimal sequence of systemic anticancer agents? [abstract IN27] (P.A. Francis, AU) Until when should ABC be treated? [abstract IN28] (A. Gennari, IT) Surgery of the primary tumor: should the recommendation be changed? [abstract IN29] (M.J. Cardoso, PT) Discussion
15:45-16:15
Coffee break
16:15-17:00 Audit. I 16:15 16:30 16:45
Survivorship in ABC (Chairs: D. Fenech, MT and C. Thomssen, DE) What are the main issues? [abstract IN30] (O. Pagani, CH) Addressing the needs of ABC patients [abstract IN31] (L.D. Shockney, US) Surviving ABC: the patient voice [abstract IN32] (E. Papadopoulos, CY)
A/V Recording during the Conference is prohibited.
5-7 NOVEMBER 2015, LISBON, PORTUGAL ABC3
21
Advanced Breast Cancer Third International Consensus Conference
17:00-18:00 Audit. I 17:00 17:15 17:30 17:45 18:00-19:30 Audit. III/IV 18:00 18:15 18:50 18:00-19:30 Audit. I
Affordability and access to care (Chairs: F. Cardoso, PT and M. Mayer, US) The cost of advanced breast cancer [abstract IN33] (R. Sullivan, UK) Are drugs really the main issue? [abstract IN34] (D.G. Taylor, UK) Can we really apply international guidelines in limited resources countries? [abstract IN35] (G.S. Bhattacharyya, IN) Is a two-speed (rich vs poor) oncology inevitable? [abstract IN36] (G.W. Sledge, US) Breast cancer patient advocacy session: ABC Advocacy: wrap-up and call to action (Chairs: M. Beishon, UK and M. Mayer, US) Quality of life and MBCVision overview Small group discussion of key issues Report from small groups and call to action Sponsored satellite symposium 4 (details are available on page 33)
A/V Recording during the Conference is prohibited.
22
ABC3 5-7 NOVEMBER 2015, LISBON, PORTUGAL
A BC 3 #ABClisbon
Consensus session Saturday, 7 November 8:30-10:30 Audit. I
Consensus session (part I) (ABC3 Chairs and Panellists)
10:30-11:00
Coffee break
11:00-11:15 Audit. I
Report from ABC Patient Advocacy Committee (S.A. Mertz, US)
11:15-12:45 Audit. I
Consensus session (part II) (ABC3 Chairs and Panellists)
12:45-13:00 Audit. I
Close
Consensus Panellists Matti S. Aapro, CH Fabrice André, FR Carlos H. Barrios, BR Jonas Bergh, SE Gouri S. Bhattacharyya, IN Laura Biganzoli, IT Fatima Cardoso, PT Maria João Cardoso, PT Dian ”CJ” Corneliussen-James, US Alberto Costa, IT/CH Giuseppe Curigliano, IT Véronique Dieras, FR Nagi S. El Saghir, LB Alexander Eniu, RO Lesley Fallowfield, UK Doris Fenech, MT Patrick Flamen, BE Prudence A. Francis, AU Karen Gelmon, CA Alessandra Gennari, IT Nadia Harbeck, DE Clifford A. Hudis, US
Bella Kaufman, IL Musa Mayer, US Hanneke Meijer, NL Shirley A. Mertz, US Larry Norton, US Shinji Ohno, JP Olivia Pagani, CH Evi Papadopoulos, CY Fedro A. Peccatori, IT/CH Frédérique Penault-Llorca, FR Martine J. Piccart, BE Jean-Yves Pierga, IT Hope S. Rugo, US Elzbieta Senkus-Konefka, PL Lillie D. Shockney, US George W. Sledge, US Sandra M. Swain, US Christoph Thomssen, DE Andrew Tutt, UK Daniel A. Vorobiof, ZA Eric P. Winer, US Binghe Xu, CN
A/V Recording during the Conference is prohibited.
5-7 NOVEMBER 2015, LISBON, PORTUGAL ABC3
23
Advanced Breast Cancer Third International Consensus Conference
Poster session BP: Best poster presentation; PO: Poster presentation BP38
Metastatic breast cancer in Canada: waiting for treatment. Niya Chari, CA
BP52
Is there a different treatment response between visceral and non-visceral metastatic breast cancer: a systematic literature review of registration trials. Rachel Würstlein, DE
BP103 Electrochemotherapy in the treatment of cutaneous metastases from breast cancer: a multicenter cohort analysis. Roberto Agresti, IT BP129 Insulin resistance (IR) and prognosis of metastatic breast cancer (MBC) patients. Nicoletta Provinciali, IT
24
PO39
Effective advocacy for women with metastatic breast cancer: a European perspective. Susan Knox, IT
PO40
Unmet needs of Australian women with metastatic breast cancer with financially dependent children: the consumer perspective. Danielle Spence, AU
PO41
Middle Eastern ABC/MBC patients: overcoming the triple-burden of stigmatization, lack of information and recurrent illness. Rania Azmi, KW
PO42
Make your dialogue count survey: addressing communication gaps between patients with advanced breast cancer, their caregivers and oncologists and understanding information and emotional needs to improve treatment and side effect management. Helen L. Coons, US
PO43
“Fight, live, keep smiling”: the first Italian blog about metastatic breast cancer (MBC) addressed to the general public. A quali-quantitative analysis of all the comments posted online on the blog of the Europa Donna Italia MBC Working Group. Francesca Balena, IT
PO44
In Our Shoes: raising the voices of MBC patients. Lori Marx-Rubiner, US
PO45
Information needs of young women with metastatic breast cancer to manage their treatment, side effects and clinical trials. Medha Sutliff, US
PO46
I AM ANNA: Exploring metastatic breast cancer through the eyes of a young woman. Shawna Ginsberg, US
PO47
Identifying deficits and needs from stakeholders about palliative care issues.
PO48
Terminology used in advanced breast cancer and the need for consistency. Maria Leadbeater, UK
PO53
Clinical impact of metronomic oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer. Miwa Fujihara, JP
PO54
A retrospective multicenter observation study in metastatic breast cancer patients: com parative analysis on efficacy of eribulin mesylate with taxane regimens (including combination with bevacizumab). Yasuko Kikuchi, JP
PO55
Efficacy and safety of eribulin in anthracycline and taxane-pretreated patients: Russian experience. Elena Kovalenko, RU
ABC3 5-7 NOVEMBER 2015, LISBON, PORTUGAL
A BC 3 #ABClisbon
PO56
BOLERO-4: A phase 2, open-label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (pts) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) metastatic or locally advanced unresectable breast cancer (BC). Thomas Bachelot, FR
PO57
Clinical efficacy of LH-RH analogue plus aromatase inhibitor in premenopausal women with estrogen receptor-positive advanced breast cancer: a single-institution retrospective study. Toshiaki Utsumi, JP
PO58
Does previous neoadjuvant/adjuvant trastuzumab influence the disease outcome of metastatic HER2 positive breast cancer patients treated with first line trastuzumab and chemotherapy. Snezana Milosevic, RS
PO59
Durable remissions with trastuzumab treatment for HER2 positive metastatic breast cancer - single center experience. Zoran Tomasevic, RS
PO60
The role of lapatinib in the management of HER2-positive metastatic breast cancer: a review of a single institution’s experience during the trastuzumab and lapatinib era. Junichiro Watanabe, JP
PO61
Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced Her2-positive breast cancer. Fadi Farhat, LB
PO62
First line trastuzumab-based therapy in HER2-positive metastatic cancer patients presenting with de novo or recurrent disease: a multicenter retrospective cohort study. Matteo Lambertini, IT
PO63
Cure in metastatic breast cancer: an aggressive approach does not appear to be the key to the black box. Uwe Güth, CH
PO64
Metronomic chemotherapy (CHT) combination of vinorelbine (VRL) and capecitabine (CAPE) in HER2- advanced breast cancer (ABC) patients (pts) does not impair Global QoL. First results of the VICTOR-2 study. Marina Elena Cazzaniga, IT
PO65
Phase II trial of metronomic combination chemotherapy with oral regimen in heavily pretreated metastatic breast cancer. Prasanna Rammohan, IN
PO66
Neoadjuvant chemotherapy for locally advanced breast cancer: a solution to avoid mastectomy. Mahmoud A. Elhussini, EG
PO67
Neo-adjuvant hormonal therapy for locally advanced breast cancer. Lika Katselashvili, GE
PO68
Triple negative breast cancer - Neoadjuvant chemotherapy response evaluation with taxane/anthracycline protocol - Single centre 5 years experience. Judy Vicente de Paolo, PT
PO69
Brachial plexopathy in metastatic breast cancer: a review of patient characteristics and diagnosis in an Irish tertiary referral centre. Connor O'Leary, IE
PO70
Estrogen receptor as a negative predictor of complete pathological response in HER2 positive locally advanced breast cancer. Rita Canario, PT
PO71
Monitoring therapy response in metastatic breast cancer using tumour markers CA15-3 and TPS. Marie Sundquist, SE
PO72
Therapeutic effect prediction based on biomarkers in the pleural effusion specimens of breast cancer patients. Rikiya Nakamura, JP
PO73
Outpatient catumaxomab therapy in metastatic breast cancer patients suffering from malignant effusions due to peritoneal or pleural carcinomatosis: a single institution experience. Christian M. Kurbacher, DE
5-7 NOVEMBER 2015, LISBON, PORTUGAL ABC3
25
Advanced Breast Cancer Third International Consensus Conference
PO74
Which is more beneficial as an initial therapy for the first distant metastasis of breast cancer: chemotherapy or endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients?: A single-center study. Jun Yamamura, JP
PO75
The CTPET/MDST ratio: an introduction of a quantitative measure of effective palliative endocrine therapy in metastatic breast cancer. Uwe G端th, CH
PO76
Therapeutic strategy for recurrent HER2-positive breast cancer patients. Akimasa Nishimura, JP
PO77
Locally advanced breast cancer In young female. The Egyptian National Cancer Institute experience. Amany Helal, EG
PO78
Elderly women and breast cancer: characterization of treatment practices. Diana Freitas, PT
PO79
Elderly metastatic breast cancer at diagnosis: a single institution experience. Amanda Nobre Carvalho, PT
PO80
Elevated neutrophil to lymphocyte ratio predicts worse survival outcome after recurrence for patients with triple negative breast cancer. Toshiaki Iwase, JP
PO81
Compliance and persistence to palliative endocrine therapy in metastatic breast cancer. Uwe G端th, CH
PO82
Epidemiology and therapeutic management of metastatic breast cancer in Bulgaria: a retrospective cohort study. Konstanta Timcheva, BG
PO83
Current status of the management of advanced RH+/Her2- breast cancer in Morocco. Narjiss Berrada, MA
PO96
Characterisation of breast cancer brain metastases through a 21-year period - a study from the Swedish Association of Breast Oncologists (SABO). Anna Thulin, SE
PO97
Brain metastases in HER2- positive breast cancer patients: a single institute experience. Tahir Mehmood, PK
PO98
Is brain metastases location associated with prognosis in breast cancer patients? Karolina Widera, PL
PO99
Treatment outcomes of breast cancer brain metastases. Ivica Ratosa, SI
PO100 IMRT-SIB for locally advanced inoperable breast cancer patients. Karolina Widera, PL PO101 Prognostic factors after gamma knife radiosurgery in breast cancer patients with brain metastases. Shoko Hayama, JP PO104 The surgical management of lung nodules in breast cancer patients. Kazuo Matsuura, JP PO105 Success and failure of primary medical, non-operative management in patients who present with stage IV breast cancer. Uwe G端th, CH PO106 N2 lymph nodes post-primary chemotherapy may predict recurrence in locally advanced breast cancer. Carol Ann Benn, ZA PO107 Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer. Anna Sukhotko, RU PO108 Novel and safe techniques in immediate breast reconstruction for locally advanced breast cancer, particularly inflammatory breast cancer. Marisse Venter, ZA PO109 The impact of locoregional treatment of primary metastatic breast cancer. Roman Liubota, UA PO110 Metastases of lobular breast carcinoma in the terminal ileum and ileocaecal valve. Sala Abdalla, UK
26
ABC3 5-7 NOVEMBER 2015, LISBON, PORTUGAL
A BC 3 #ABClisbon
PO112 Efficacy of NEPA, the first combination antiemetic agent, in patients with breast cancer receiving anthracycline/cyclophosphamide (AC) or non-AC chemotherapy. Hope Rugo, US PO114 Using of hepatoprotectors in the drug treatment of patients with advanced breast cancer. Jamshid Ibragimov, UZ PO115 The emotional toll of metastatic breast cancer on young women. Medha Sutliff, US PO116 The last quarter of a honeymoon – A wedding’s story. Jose Pereira, PT PO117 Can we make a portrait of women with inoperable locally advanced breast cancer? The experience of the Breast Unit of Southern Switzerland (CSSI). Giacomo Montagna, CH PO122 Sodium fluoride PET/CT: a superior imaging modality in evaluation of osseous metastatic disease. Emily Harrold, IE PO130 Clinical utility of the expression of HER3, HER4, PTEN and IGF1R in HER2-positive advanced or metastatic breast cancer. Hiroki Ito, JP PO131 Heterogeneity in the expression of hormone receptors and HER2 between the primary breast cancer and pulmonary metastasis. Masako Sato, JP PO132 Apoptotic activities of recombinant cell surface receptor fas within tumor microenvironment of breast carcinoma. Medhat M. Anwar, EG PO133 Differential expression of plasma membrane proteins in inflammatory breast cancer via stable isotope labeled amino acids in culture (SILAC). Michelle M. Martinez-Montemayor, PR PO134 Analysis of primary breast cancer (BC) expression of programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) to determine associations with clinical characteristics and outcomes. Neelima Vidula, US PO135 At a glance the BRCAs epigenetic study in Padang, west Sumatera, Indonesia. Wirsma A. Harahap, ID PO138 P-cadherin: a candidate biomarker for axillary-based breast cancer decisions in clinical practice. Maria Rita Dionisio, PT PO139 Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence free survival and development of bone metastases in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657). Neelima Vidula, US PO140 Changing in tumor biology of triple negative breast cancer between primary and metastatic lesions. Marijana Milovic-Kovacevic, RS PO141 Sucessfull use of HER2 targeted agents in patients with heavily pretreated HER2negative metastatic breast cancer presenting with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells. Christian M. Kurbacher, DE PO142 Evolution of the expression of circulating tumor cells (CTC) and CK-19 mRNA (CK19) as prognostic factors in heavily pretreated metastatic breast cancer. Serafin Murillo Morales, ES PO143 Prognostic impact of circulating tumor cell clusters and apoptosis in metastatic breast cancer. Sara Jansson, SE PO144 Synergistic antitumor effects of crocin combined with hyperthermia on breast cancer cells. Reyhane Hoshyar, IR PO145 ICORG 13-01 ABC survey: are we meeting the needs of patients with advanced breast cancer (ABC) in Ireland? A nationwide survey. Jodie E. Battley, IE
5-7 NOVEMBER 2015, LISBON, PORTUGAL ABC3
27
Advanced Breast Cancer Third International Consensus Conference
Abstract presenters Sala Abdalla, University Hospital Lewisham, Department of General Surgery, London, UK Roberto Agresti, Istituto Nazionale dei Tumori, Breast Surgery Unit, Milano, IT Medhat M. Anwar, Medical Research Institute University of Alexandria, Experimental and Clinical Surgery Department, Alexandria, EG Rania Azmi, “Survive & Thrive” Initiative, For Cancer Patients Support, Salmiya, KW Thomas Bachelot, Centre Léon Bérard, Breast Cancer Unit and Clinical Trial Unit, Lyon, FR Francesca Balena, Europa Donna Italia, MBC Working Group, Milano, IT Jodie E. Battley, Cork University Hospital, Medical Oncology, Cork, IE Carol Ann Benn, Helen Joseph Breast Care Clinic, Johannesburg ZA and University of the Witwatersrand, Faculty of Health Sciences, Department of Surgery, Johannesburg, ZA Narjiss Berrada, National Institute of Oncology, Medical Oncology Department, Rabat, MA Rita Canario, Instituto Português de Oncologia de Coimbra Francisco Gentil, Medical Oncology Department, Coimbra, PT Marina Elena Cazzaniga, San Gerardo Hospital, Medical Oncology Department, Monza, IT Niya Chari, Canadian Breast Cancer Network, Government Relations, Ottawa, CA Helen L. Coons, Women's Mental Health Associates, Health Psychology, Denver, US Maria Rita Dionisio, Hospital de Santa Maria CHLN Lisboa, Dept. of Medical Oncology, Lisbon and IPATIMUP and Instituto de Investigação e Inovação em Saúde, Cancer Genetics, Porto, PT Mahmoud A. Elhussini, Alexandria Faculty of Medicine, Surgical Oncology Unit, Alexandria, EG Fadi Farhat, Saint Joseph University, Faculty of Medicine-Hematology-Oncology, Beirut, LB Diana Freitas, Hospital de Braga, Medical Oncology Department, Braga, PT Miwa Fujihara, Hiroshima City Hiroshima Citizens Hospital, Breast Surgery, Moto-machi, Naka-ku, Hiroshima, JP Shawna Ginsberg, Rethink Breast Cancer, Breast Cancer Department, Toronto, CA Uwe Güth, Cantonal Hospital Winterthur, Obstetrics & Gynecology, Winterthur, CH and University Hospital Basel, Gynecology & Obstetrics, Basel, CH Wirsma A. Harahap, Medical Faculty Andalas University/Dr. M. Djamil Hospital, Department of Surgery, Padang, ID Emily Harrold, Cork University Hospital, Medical Oncology Department, Cork, IE Shoko Hayama, Chiba University, General Surgery Department, Chiba City, Japan, JP Amany Helal, National Cancer Institute, Medical Oncology, Cairo, EG Reyhane Hoshyar, Birjand University of Medical Sciences, Faculty of Medicine, Department of Biochemistry, Birjand, IR
28
ABC3 5-7 NOVEMBER 2015, LISBON, PORTUGAL
A BC 3 #ABClisbon
Marc Hurlbert, Avon Foundation for Women, Breast Cancer Crusade, New York, US and Metastatic Breast Cancer Alliance, Advocacy, New York, US Jamshid Ibragimov, National Cancer Research Center, Chemotherapy Department, Tashkent, UZ Hiroki Ito, Kyorin University Hospital, Breast Surgery Department, Tokyo, JP Toshiaki Iwase, Chiba University Hospital, Breast and Thyroid Surgery, Chiba, JP Sara Jansson, Lund University, of Clinical Sciences, Division of Oncology and Pathology, Lund, SE Lika Katselashvili, Research Institute of Clinical Medicine, Department of Oncology, Tbilisi, GE Yasuko Kikuchi, International University of Health and Welfare Mita Hospital, Breast Center, Tokyo, JP Susan Knox, Europa donna - The European Breast Cancer Coalition, Milan, IT Elena Kovalenko, Russian Scientific Oncological Center, Research of New Antitumor Agents, Moscow, Russian Federation, RU Christian M. Kurbacher, Gynecologic Center Bonn-Friedensplatz, Gynecologic Oncology Department, Bonn, DE Matteo Lambertini, IRCCS AOU San Martino-IST, Department of Medical Oncology, U.O. Oncologia Medica 2, Genova, IT Maria Leadbeater, Ashgate Hospice, Macmillan Clinical Nurse Specialist Palliative Care, Old Brampton, Chesterfield, UK Roman Liubota, National Medical University named after O.O. Bogomolets, Oncology Department, Kiev, UA Norbert Marschner, Praxis für interdisziplinäre, Onkologie & Hämatologie, Interdisziplinäre Onkologie & Hämatologie, Freiburg i. Br., DE Michelle M. Martinez-Montemayor, Universidad Central del Caribe School of Medicine, Department of Biochemistry, Bayamon, PR Lori Marx-Rubiner, METAvivor Research and Support, Annapolis, US Kazuo Matsuura, Hiroshima Prefectural Hospital, Breast Surgery, Hiroshima, JP Tahir Mehmood, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Radiation Oncology, Lahore, PK Snezana Milosevic, Institute for Oncology and Radiology of Serbia, Daily Hospital for Chemotherapy, Belgrade, RS Marijana Milovic-Kovacevic, Institute for Oncology and Radiology of Serbia, Department of Medical Oncology, Belgrade, RS Giacomo Montagna, Ente Ospedaliero Cantonale, Department of Obstetrics and Gyneacology and Breast Unit of Southern Switzerland (CSSI), Lugano, CH Serafin Murillo Morales, Hospital Universitari Arnau de Vilanova de Lleida, Department of Medical Oncology, Lleida, ES Rikiya Nakamura, Chiba Cancer Center Hospital, Breast Surgery, Chuou Chiba, JP Akimasa Nishimura, Hirosaki University, Surgery, Hirosaki, JP Amanda Nobre Carvalho, Algarve Hospital Centre, Medical Oncology Department, Faro, PT
5-7 NOVEMBER 2015, LISBON, PORTUGAL ABC3
29
Advanced Breast Cancer Third International Consensus Conference
Connor O'Leary, Cork University Hospital, Department of Medical Oncology, Cork, IE Jose Pereira, Hospital Sao Francisco Xavier, Oncology and Medical Departments, Lisbon, PT Nicoletta Provinciali, E.O. Ospedali Galliera, Division of Medical Oncology, Genoa, IT Prasanna Rammohan, Madras Medical College, Medical Oncology, Chennai, Tamilnadu, IN Ivica Ratosa, Institute of Oncology Ljubljana, Department of Radiation Oncology, Ljubljana, SI Hope S. Rugo, University of California San Francisco Comprehensive Cancer Center, Hematology/Oncology, San Francisco, US Masako Sato, NHO Hokkaido Cancer Center, Breast Surgery, Sapporo, Hokkaido, JP Danielle Spence, Breast Cancer Network Australia, Camberwell, Victoria, AU Anna Sukhotko, Moscow P.A. Gerzen's Cancer Research Institute - The National Medical Research Radiologic Center of the Ministry of Health of the Russian Federation, Department of Oncology and Reconstructive-plastic Surgery of the Breast and Skin, Moscow, RU Marie Sundquist, County Hospitals, Breast Unit Surgery, Kalmar, SE Medha Sutliff, Young Survival Coalition, National Programs, New York, US Konstanta Timcheva, Women’s Health Hospital “Nadezhda”, Medical Oncology Clinic, Sofia, BG Anna Thulin, Institution of Clinical Sciences, Department of Oncology, Gothenburg, SE Uhi Toh, Kurume University School of Medicine, Department of Surgery, Kurume, JP Zoran Tomasevic, Institute for Oncology and Radiology of Serbia, Daily Hospital, Belgrade, RS Toshiaki Utsumi, Fujita Health University, Breast Surgery Department, Aichi, Toyoake, JP Marisse Venter, Breast Care Center of Excellence, Breast Oncology, Johannesburg, ZA Judy Vicente de Paolo, Portuguese Institute of Oncology, Medical Oncology Department, Coimbra, PT Neelima Vidula, University of California, San Francisco, Hematology/Oncology Department, San Francisco, US Junichiro Watanabe, Shizuoka Cancer Centre, Breast Oncology Department, Shizuoka, JP Karolina Widera, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Outpatient Clinic, Gliwice, PL Rachel Würstlein, Medical Center of the Ludwig-Maximilians-University, Department for Gynecology of Obstetrics and Comprehensive Cancer Center of LMU, Munich, DE Jun Yamamura, Sakai City Hospital, Breast Surgery Department, Sakai City, JP
30
ABC3 5-7 NOVEMBER 2015, LISBON, PORTUGAL
15th St.Gallen International Breast Cancer Conference 2017 Primary Therapy of Early Breast Cancer – Evidence, Controversies, Consensus
©WienTourismus / Claudio Alessandri
7
15 – 18 March 2017, ACV (Austria Center Vienna), Vienna / Austria
First Announcement Information St.Gallen Oncology Conferences (SONK) c /o Tumor and Breast Center ZeTuP Rorschacherstrasse 150 CH-9006 St.Gallen / Switzerland info@oncoconferences.ch www.oncoconferences.ch
Advanced Breast Cancer Third International Consensus Conference
Sponsored satellite symposia Thursday, 5 November 11:00-12:30
Sponsored satellite symposium 2 Novartis Oncology Treatment strategies for optimizing the treatment experience for patients with advanced breast cancer: shared decision-making and effective clinical management (Chair: J. Cortés, ES) 11:00 Welcome and introduction (J. Cortés, ES) 11:05 Pathways to endocrine resistance in HR+ aBC (G. Arpino, IT) 11:20 Dual blockade strategies to enhance endocrine sensitivity in HR+ aBC
(T. Bachelot, FR) 11:45 Maximizing treatment benefit from dual blockade in HR+ aBC (J. Cortés, ES) 12:10 The changing landscape of HR+ aBC (G. Arpino, IT) 12:20 Interactive panel discussion and close (All speakers)
Symposium faculty: Grazia Arpino, University of Naples Federico II, Naples, IT Thomas Bachelot, Centre Léon-Berard, Lyon, FR Javier Cortés, Vall d’Hebron University Hospital, Barcelona, ES
18:00-19:30
Sponsored satellite symposium 3 Pfizer Oncology Advances in ER+ HER2- breast cancer: targeting the cell cycle (Chair: A. Di Leo, IT) 18:00 Welcome and introduction (A. Di Leo, IT) 18:10 Improving outcomes in metastatic breast cancer patients: changing
perceptions (J. Gralow, US) 18:30 Metastatic breast cancer: beyond standard endocrine therapy (J. Crown, IR) 18:50 New treatment algorithms: focusing on patients’ needs
(A. Llombart-Cussac, ES) 19:20 Closing remarks and Q&A (All speakers)
Symposium faculty: John Crown, National Institute for Cellular Biotechnology, Dublin City University, Dublin, IR Angelo Di Leo, Istituto Toscano Tumori, Hospital of Prato, Prato, IT Julie Gralow, Seattle Cancer Care Alliance, University of Washington, Seattle, US Antonio Llombart-Cussac, Hospital Arnau de Vilanova, Valencia, ES
32
ABC3 5-7 NOVEMBER 2015, LISBON, PORTUGAL
A BC 3 #ABClisbon
Friday, 6 November 18:00-19:30
Sponsored satellite symposium 4 Eisai What’s new since ABC2? Recent advances in chemotherapy for ABC (Chair: X. Pivot, FR - Moderator: E.C. Antoine, FR) 18:00 Welcome and introductions (X. Pivot, FR) 18:05 Decision making in chemotherapy: where are we now? (X. Pivot, FR) 18:25 New data for a new authorisation in second-line ABC (E.C. Antoine, FR) 18:45 From clinical trials to clinical practice - level of evidence (J.M. Grouin, FR) 19:10 Panel discussion and conclusions (All speakers)
Symposium faculty: Eric-Charles Antoine, Institut du Sein - Henri Hartmann, Paris, FR Jean-Marie Grouin, Université de Rouen, Rouen, FR Xavier Pivot, Centre Hospitalier Universitaire, Hôpital Jean Minjoz, Besançon, FR
Sponsors ESO wishes to express its appreciation for the following sponsors for having granted their participation and support to ABC3.
Travel grants, support to the Conference and to the patient advocacy activities
Participating organisations and companies
5-7 NOVEMBER 2015, LISBON, PORTUGAL ABC3
33
Advanced Breast Cancer Third International Consensus Conference
Disclosure of conflict of interest Faculty members have been asked to disclose any potential conflict of interest in relation to their participation in the Conference. Potential conflict of interest are considered any of the following: • Any financial interest in or arrangement with a company whose products or services are
discussed in the lecture or that might be considered as part of the consensus process. • Any financial interest in or arrangement with a competing company. • Any other financial relationship, direct or indirect, or other situations that might raise the
question of bias in the work presented or in the participation in the consensus process, including pertinent commercial or other sources of funding for the speaker or panellist or for the associated department or organisation, personal relationships or direct academic competition.
ABC3 Chairs, faculty and panel members Matti S. Aapro:
No significant relationships.
Consultant for Abraxis, Amgen, BMS, CarisLifeSciences, Celgene, Eisai, GenomicHealth, GSK, Helsinn, Hospira, Novartis, Merck, Merck Serono, Pfizer, Pierre Fabre, Roche, Sandoz, Teva, Vifor and has received honoraria for lectures at symposia f Amgen, Astellas, Bayer Schering, Cephalon, Eisai, Ferring, Genomic Health, GSK, Helsinn, Hospira, Ispen, JnJ OrthoBiotech, Merck, Merck Serono, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Sanofi, Teva, Vifor.
Lisa A. Carey:
Fabrice André:
No significant relationships.
No significant relationships.
Giuseppe Curigliano:
Sam Aparicio:
No significant relationships.
Receipt of grants/research supports: Takeda Biopharma.
Véronique Dieras:
Carlos H. Barrios: Receipt of grants/research supports: Amgen, Astra Zeneca, Boehringer-Ingelheim, GSK, Novrtis, Pfizer, Roche/Genentech, Eisai, Lilly, Sanofi-Aventis, Celgene and has received honoraria or consultation fees from: BoehringerIngelheim, GSK, Novartis, Pfizer, Roche/Genentech.
Marc Beishon: Receipt of honorarium: Pfizer.
Jonas Bergh: Receipt of grants/research supports paid to Karolinska Institute and University Hospital: Roche, Bayer, Sanofi-Aventis, Astra Zeneca, Pfizer, Merck, Amgen.
Gouri S. Bhattacharyya: No significant relationships.
No significant relationships.
Sarbani Chaudhuri: Full time employee of Pfizer.
Robert E. Coleman: Receipt of grants/research supports: Bayer, Celgene. Expert testimony: Novartis.
Dian “CJ” M. Corneliussen-James: Receipt of honoraria for work for ABC3.
Alberto Costa:
Receipt of honoraria or consultation fees: Roche, Genentech, Novartis, Eisai. Participation in a sponsored speakers bureau: Roche, Pfizer.
Nagi S. El Saghir: Receipt of grants/research supports: GSK, Novartis, Roche. Receipt of honoraria or consultation fees: lecture honoraria: Novartis, Roche, MSD, AstraZeneca, Celgene.
Alexander Eniu: Receipt of grants/research supports: Astra Zeneca, Roche, Celltrion, Pfizer, Mylan.
Lesley Fallowfield: No significant relationships.
Doris Fenech: No significant relationships.
Patrick Flamen:
No significant relationships.
Receipt of grants/research supports: Sirtex/Bayer, receipt of honoraria or consultation fees: Sirtex/Bayer.
Fatima Cardoso:
Prudence A. Francis:
Laura Biganzoli: Receipt of honoraria or consultation fees: Astellas/medication, Astra Zeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GSK, Merck-Sharp, Merus BV, Novartis, Pfizer, Roche, Sanofi. 34
Maria João Cardoso:
ABC3 5-7 NOVEMBER 2015, LISBON, PORTUGAL
Conference travel support from Roche and Amgen.
A BC 3 #ABClisbon
Karen Gelmon: Receipt of honoraria or consultation fees: Roche, Genetech, Astra Zeneca, Pfizer, Nanostring, Novartis.
Alessandra Gennari: Receipt of grants/research supports: Celgene/Teva, receipt of honoraria or consultation fees: Celgene, Teva, Eisai, Pierre Fabre, participation in a sponsored speakers bureau: Celgene, Teva, Eisai.
Nadia Harbeck: Receipt of honoraria or consultation fees: Amgen, Astra Zeneca, Celgene, Novartis, Pfizer, Roche.
Jens Hoffmann: Employee or stock shareholder: EPOExperimental Oncology and Pharmacology Berlin-Buch GmbH, Bayer Pharma AG.
Clifford A. Hudis: No significant relationships
Bella Kaufman: Receipt of honoraria: AstraZeneca, Novartis, Pfizer and Roche.
Ian E. Krop: Receipt of grants/research supports: Genentech/Roche.
Stella Kyriakides: No significant relationships.
Musa Mayer: No significant relationships.
Hanneke Meijer: No significant relationships.
Shirley A. Mertz: Receipt of honoraria or consultation fees: Pfizer.
Larry Norton: No significant relationships.
Shinji Ohno: No significant relationships.
Olivia Pagani: Participation in a sponsored speakers bureau: Novartis, Celgene.
Evi Papadopoulos: No significant relationships.
Fedro A. Peccatori: No significant relationships.
Frédérique Penault-Llorca: No significant relationships.
Martine J. Piccart: Board member: PharmaMar; consultant (honoraria: Amgen, Astellas, AstraZeneca, Bayer, Eli Lilly, Invivis, MSD, Novartis, Pfizer, Roche-Genentech, Sanofi Aventis, Symphogen, Synthon, Verastem; research grants to my institute most companies.
Jean-Yves Pierga: Receipt of grants/research supports: Roche, Jansen Diagnostics; receipt of honoraria or consultation fees: Roche, GSK, Novartis,
Genomic Health; participation in a sponsored speakers bureau: Roche, Novartis.
Fausto Roila: No significant relationships.
Hope S. Rugo: Receipt of grants/research supports: GSK, Genentech/Roche, Novartis, Merck, Pfizer, Eisai, Macrogenics, Amgen, Biomarin, Plexxikon.
Kimberly A. Sabelko: No significant relationships.
Elzbieta Senkus-Konefka: Receipt of honoraria or consultation fees: Astellas, Janssen, Bayer, Roche, AstraZeneca, GSK, Amgen, Pierre Fabre, Teva; travel expenses: Roche, Novartis, Janssen, Astellas, Amgen, Sandoz, Ipsen, Bayer, Egis.
Lillie D. Shockney: No significant relationships.
George W. Sledge: Member Board of Directors: Syndax; member SAB: Symphogen.
Danielle Spence: No significant relationships.
Richard Sullivan: Receipt of unrestricted research grant.
Sandra M. Swain: Receipt of grants/research supports: Genentech/Roche, Pfizer, Puma; receipt of honoraria or consultation fees: Genentech/Roche, Clinigen, Astra Zeneca; participation in a sponsored speakers bureau; nonpromotional Genentech/Roche; spouse/partner: travel: Genentech/Roche; travel: Genentech/Roche.
David G. Taylor: Receipt of grants/research supports: Novartis; receipt of honoraria or consultation fees: Novartis.
Christoph Thomssen: No significant relationships.
Luzia Travado: Receipt of honoraria or consultation fees: Roche, Novartis.
Andrew Tutt: Receipt of grants/research supports: Vertex, Astra Zeneca, Myriad Genetics, Roche; receipt of honoraria or consultation fees: Verte, Eisai; named on patent (King’s College London) Genome Instability; rewards to Inventors Scheme- Institute of Cancer Research ARP inhibitors BRCA1/2 Associated Cancers.
Daniel A. Vorobiof: No significant relationships.
Eric Winer: Receipt of grants/research supports: Genentech/Roche.
Binghe Xu: No significant relationships.
5-7 NOVEMBER 2015, LISBON, PORTUGAL ABC3
35
PREVENTION IN GYNAECOLOGICAL MALIGNANCIES SEPTEMBER 08-10, 2016 l ANTALYA, TURKEY
ANTALYA, TURKEY
www.esgo.org
EBCC 10
European Breast Cancer Conference
EBCCouncil
Multidisciplinary Innovation in Breast Cancer Care Be part of a unique gathering of physicians, scientists and patients
Why Participate at EBCC10? â—ź New, practice changing data gets global visibility â—ź Largest breast cancer conference outside the US â—ź A new and stimulating scientiďŹ c programme: burning issues at each step of the breast cancer journey â—ź Unique multidisciplinary meeting driving the work of multidisciplinary breast teams â—ź Setting direction for patient advocacy efforts â—ź Special focus on regulatory developments in Europe
9 - 11 MARCH 2016
AMSTERDAM THE NETHERLANDS
Isaac IsraÍls :RPDQ LQ SURÀOH LQ IURQW RI 9DQ *RJK¡V VXQà RZHUV 2LO RQ FDQYDV ² [ FP
0XVHXP GH )XQGDWLH =ZROOH DQG +HLQR :LMKH 7KH 1HWKHUODQGV
Advantageous rates for different delegate profiles Incentive for Breast Team registration
REGULAR RATE REGISTRATION DEADLINE: 25 JANUARY 2016
www.ecco-org.eu/EBCC #EBCC10
Breast Centres Network Breast Centres
A project of
Synergy among Breast Units
Network
Photo: Itsy, bitsy spider... - Photographer: © 2012 Daniel Sjostrom
Need to quickly contact a breast expert collegue? Is your Breast Unit organised according to state-of-the-art international standards? Don’t miss the opportunity to discover more and improve your Breast Unit!
Become a Breast Centres Network Member www.BreastCentresNetwork.org Membership is free! Breast Centres Network is the first international network of clinical centres exclusively dedicated to the diagnosis and treatment of breast cancer. It is a project of ESO (European School of Oncology) with the aim to promote and improve breast cancer care in Europe and throughout the world. Our network includes Breast Units (Multidisciplinary Breast Centres) that fulfill minimum requirements (see Eligibility Gate) to be considered referral centres. Organisation of Multidisciplinary Breast Units is recommended by EUSOMA, Europa Donna (European Breast Cancer Coalition) and the European Parliament. In the US, breast center accreditation is offered by the National Accreditation Program for Breast Centers. We offer an online Breast Unit Directory that provides detailed information at a glance about our members in an attempt to broadcast the state-of-the-art international standards for multidisciplinary breast cancer care.
than t e r Mo Breas 220 nits! U
And it’ll really make a difference to your center!
CIAL! O S O G
_ESO #BCN
CDK4/6
DRIVE CELL PROLIFERATION
Multiple mitogen signaling pathways drive cell cycle progression.1
Downstream, these pathways trigger cyclin D1 to form a complex with cyclindependent kinases 4 and 6 (CDK4/6).2 The cyclin D1-CDK4/6 complex phosphorylates the retinoblastoma protein (RB), releasing E2F and allowing for gene transcription and passage from the G1 phase to the S phase of the cell cycle.3
P =phosphorylation; E2F=E2F transcription factor.
In preclinical studies, inhibiting CDK4/6 in tumor cells blocked RB phosphorylation and, therefore, cell proliferation.4,5 Pfizer Oncology is focusing on the research and development of CDK4/6 inhibition. References: 1. Lukas J, Bartkova J, Bartek J. Mol Cell Biol. 1996;16(12):6917-6925. 2. Prall OWJ, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL. J Biol Chem. 1997;272(16):10882-10894. 3. Ji J-Y, Dyson NJ. In: Enders GH, ed. Cell Cycle Deregulation in Cancer. New York, NY: Humana Press; 2010:23-42. 4. Rocca A, Farolfi A, Bravaccini S, Schirone A, Amadori D. Expert Opin Pharmacother. 2014;15(3):407-420. 5. Fry DW, Harvey PJ, Keller PR, et al. Mol Cancer Ther. 2004;3(11):1427-1437. CDK654715
April 2014
0OTHE1509007
September 2015
Š2014 Pfizer Inc. All rights reserved.
INSIDE TRACK CONFERENCE
3RD BREAST CANCER IN YOUNG WOMEN CONFERENCE 10-12 November 2016 Lugano, Switzerland Chair: O. Pagani, CH
Scientific Committee: H.A. Azim Jr, BE - F. Cardoso, PT - S. Loibl, DE S. Paluch-Shimon, IL - A.H. Partridge, US F.A. Peccatori, IT Organising secretariat: Via Turati, 29 - 20121 Milan - Italy Francesca Marangoni - fmarangoni@eso.net - Tel: +39 02 85464525
FURTHER INFORMATION AVAILABLE AT: WWW.ESO.NET
#BCYlugano